openPR Logo
Press release

Dilated Cardiomyopathy Market Regulations and Competitive Landscape Outlook to 2027

02-06-2017 12:51 PM CET | Advertising, Media Consulting, Marketing Research

Press release from: Future Market Insights

Dilated Cardiomyopathy Market Regulations and Competitive

Dilated cardiomyopathy is condition caused due to enlargement of left ventricle in the heart. In this state left ventricle gets enlarged, and the heart walls become thinner to pump blood from heart to other body parts of the body. Dilated cardiomyopathy can be developed at any age however it is more common in the people age between 20 to 60 years. In some cases, right ventricle also might be affected due to myopathy. Dilated cardiomyopathy is often caused by genetic mutations and non-genetic conditions like exposure to toxins, autoimmune diseases, heart valve abnormalities and diabetes disease conditions. However, there was no drug approved by FDA to treat dilated cardiomyopathy conditions. Companies are actively working on to develop molecules to treat dilated cardiomyopathy conditions. Array BioPharma carrying out Phase 2 clinical trial for ARRY-797 that inhibits p38 mitogen-activated kinase inhibitor to treat dilated cardiomyopathy. In December 2015, U.S. FDA gave Orphan drug status to the Vasomera (PB1046) molecule developed by PhaseBio Pharmaceuticals that is used treat X-linked dilated cardiomyopathy conditions. Vericel Corporation working on innovative concept to treat dilated cardiomyopathy conditions. Company has developed Ixmyelocel-T, multicellular therapy to treat dilated cardiomyopathy.

Dilated Cardiomyopathy Market: Drivers and Restraints

Globally increase in incidences of congestive heart failure conditions which is leading cause of dilated cardiomyopathy conditions. According to American Heart Association, around 5.3 million Americans have congestive heart failure within an incidence of 660,000 cases diagnosed yearly this signifies potential of the market. The major restraints for the market lack of proper drugs, increase in usage of defibrillators and pacemakers are effecting growth of this market.

Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-2830

Dilated Cardiomyopathy Market: Segmentation

The global Dilated Cardiomyopathy Market is classified on the basis of drug class, distribution channel and geography.

Based on drug class, the dilated cardiomyopathy market is segmented into the following:

Angiotensin-converting enzyme (ACE) inhibitors

Angiotensin II receptor blockers

Beta blockers

Diuretics

Blood thinning medications

Cardiac glycosides

Based on distribution channel, the dilated cardiomyopathy market is segmented into the following:

Retail Pharmacies

Online Pharmacies

Hospital Pharmacies

Mail order Pharmacies

Dilated Cardiomyopathy Market: Overview

Normally to treat dilated cardiomyopathy conditions, physicians use the drugs that can treat for congestive heart failure conditions this is due to lack of drugs for dilated cardiomyopathy conditions. Angiotensin receptor blockers occupy the major market share followed by beta blockers by beta blockers. In case of distribution channel, retail pharmacies hold the major market share followed by hospital pharmacies due to easy availability of drugs.

Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-2830

Dilated Cardiomyopathy Market: Regional Overview

Dilated Cardiomyopathy Market is classified into seven regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America occupies the significant market share in dilated cardiomyopathy market. Due to high incidence rates of congestive heart failures in the region. Next to North America, Europe holds the second leading market share for dilated cardiomyopathy conditions. According to European Federation of Pharmaceutical Industries and Associations, over 6000,000 are admitted to hospital, and 55,000 deaths are caused due to the congestive heart failure conditions in Europe. However, APEJ market is expected to grow over the forecast due to increase in awareness and increasing demand for generic drugs are responsible for growth of the market over the forecast period.

Dilated Cardiomyopathy Market: Players

Some of the players in the dilated cardiomyopathy Pfizer Inc., Array BioPharma, Vericel Corporation,PhaseBio Pharmaceuticals, Pfizer Inc., GlaxoSmithKline plc, Johnson and Johnson, Merck & Co., Inc, Teva Pharmaceuticals, Astrazeneca plc and Sanofi

Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services, which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, an aerial view of the competitive framework, and future market trends.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Website: www.futuremarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Dilated Cardiomyopathy Market Regulations and Competitive Landscape Outlook to 2027 here

News-ID: 429018 • Views:

More Releases from Future Market Insights

Global Lithium Ion Battery Separator Market Projected to Reach US$ 3,256.7 Million by 2032
Global Lithium Ion Battery Separator Market Projected to Reach US$ 3,256.7 Milli …
The lithium-ion battery separator is a critical component in lithium-ion batteries, responsible for preventing short circuits and ensuring safe and efficient battery performance. It acts as a physical barrier between the positive and negative electrodes, allowing lithium ions to pass through while blocking the flow of electrons. With advancements in separator technology, these separators play a key role in enhancing battery capacity, cycle life, and overall safety in various applications,
Industrial Drums Market on a Trajectory to Reach US$ 17.6 Billion by 2027, Bolstered by a Robust 7.1% CAGR from 2022
Industrial Drums Market on a Trajectory to Reach US$ 17.6 Billion by 2027, Bolst …
The Industrial Drums Market is experiencing a steady and promising trajectory, with an estimated value of US$ 12.5 billion in 2022, projected to escalate to US$ 17.6 billion by 2027 at a commendable Compound Annual Growth Rate (CAGR) of 7.1%. This growth is substantiated by a 6.6% CAGR in volume during 2022-27, as per Future Market Insights. Anticipated to expand 1.5 times within this period, the market presents alluring prospects for industry
Supermarkets, Convenience Stores, and Eco-friendly Choices Fuel the Expansion of the Metal Cans Industry, Catering to Health-conscious and Environmentally-aware Consumers
Supermarkets, Convenience Stores, and Eco-friendly Choices Fuel the Expansion of …
The metal cans market is predicted to grow at a CAGR of 5% over the forecast period, according to research by Future Market Insights. The industry's estimated value is expected to increase from US$ 56 Bn in 2023 to US$ 91.1 Bn by 2033. The market for metal cans has been driven by the heightened demand for the product in food and beverages industry. Metal cans helps prolong shelf-life of perishable
Folding IBCs Market Poised for Growth: Expected to Reach US$ 528 Million by 2027 with a 4.8% CAGR
Folding IBCs Market Poised for Growth: Expected to Reach US$ 528 Million by 2027 …
The folding intermediate bulk containers (IBCs) market is on a growth trajectory, with an estimated value of US$ 418 million in 2022, projected to reach US$ 528 million by 2027, showcasing a Compound Annual Growth Rate (CAGR) of 4.8%. Remarkably, the China folding IBCs market defied initial pandemic-related skepticism and is anticipated to grow by 6.9% year on year in 2022. Despite global challenges, China's folding IBCs market is poised to contribute

All 5 Releases


More Releases for Dilated

Global Dilated Cardiomyopathy Market Insights, Forecast
Dilated Cardiomyopathy (DCM) refers to the cardiac hypertrophy, cannot effectively pump blood. Dilated Cardiomyopathy (DCM) is due to genetic or other disease caused by a heart disease, it respectively affect the ventricles of the heart and heart, the inferior vena chamber and the upper Chambers of the heart. The global Dilated Cardiomyopathy market is valued at 180 million US$ in 2018 and will reach 290 million US$ by the end
Dilated Cardiomyopathy Market Opportunity Analysis, 2026 – 2026
Dilated cardiomyopathy (DCM) is a condition in which the heart gets enlarged and is not able to efficiently pump blood. The reduced heart function can affect the functioning of other organs such as lungs, liver, and kidney. The heart muscles begin to dilate (stretches), which result in thinning and increased area of the chamber, further it spreads to the right ventricle and atria’s. As the heart chambers dilate, heart muscles
Dilated Cardiomyopathy Market – Global Industry Insights,2025
Dilated cardiomyopathy (DCM) is a condition in which the heart gets enlarged and is not able to efficiently pump blood. The reduced heart function can affect the functioning of other organs such as lungs, liver, and kidney. The heart muscles begin to dilate (stretches), which result in thinning and increased area of the chamber, further it spreads to the right ventricle and atria’s. As the heart chambers dilate, heart muscles
Dilated Cardiomyopathy - Pipeline Review, H1 2017
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Dilated Cardiomyopathy - Pipeline Review, H1 2017, provides an overview of the Dilated Cardiomyopathy (Cardiovascular) pipeline landscape. Dilated cardiomyopathy (DCM) is a condition in which the heart's ability to pump blood is decreased because the heart's main pumping chamber, the left ventricle, is enlarged and weakened. Symptoms include Fatigue and weakness, Shortness of breath (dyspnea), lightheadedness, dizziness or fainting, persistent cough or wheezing,
Dilated Cardiomyopathy Therapeutics Market Research Report Forecast to 2020
Transparency Market Research in a recent publication says competition in the global dilated cardiomyopathy therapeutics market is expected to grow as prominent companies strive to develop effective drugs for the treatment of dilated cardiomyopathy. For example, in February 2017, Myokardia Inc., a biopharmaceutical company, announced first time administer of MYK-491 to a batch of healthy subjects. MYK-491 is a treatment for dilated cardiomyopathy which is in Phase 1. Keen players in
Dilated Cardiomyopathy Therapeutics Market Research Report Forecast
A new market research report has been recently published by Transparency market research, a leading market intelligence firm. The research report, titled “Dilated Cardiomyopathy Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020”, presents a market overview, market drivers, opportunities, challenges, product segmentation, and competitive landscape. The research report also features inputs and recommendations from industry experts and professionals to help the